Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02677298 · ClinicalTrials.gov registry record · Phase 3
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
A Phase 3 study, sponsored by Croma-Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 784
- Enrollment target
NCT02677298: Completed Phase 3 study, sponsored by Croma-Pharma.
NCT02677298 is a Phase 3 study that has completed, run by Croma-Pharma. The registered enrollment target is 784 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02677298, a Phase 3 study, has completed, sponsored by Croma-Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 784 participants
- Enrollment target
Study Summary
The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
Primary Outcome
The primary endpoint is the percentage of subjects among BoNT/A-DP and placebo groups with a Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 4 visit (of the first treatment cycle) relative to baseline (responders), based on both the investigators' and the subjects' in-clinic assessments. Thus, the primary endpoint is a composite endpoint comprising investigator and subject assessments of treatment effectiveness. FWS scores are a
Interventions
- DRUG Placebo
- DRUG Botulinum Toxin A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 784 participants |
| Start Date | 2016-03-02 |
| Est. Completion | 2017-11-16 |
| Phase | Phase 3 |
What the finished NCT02677298 record still lists
NCT02677298 is an interventional study that assigns participants to a tested intervention. The registered 784 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02677298 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02677298 about?
NCT02677298 is a clinical study titled "Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I". The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
What is the current status of trial NCT02677298?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 784 participants. The study started on 2016-03-02. Estimated completion is 2017-11-16.
What interventions are being tested in trial NCT02677298?
The interventions under investigation include: Placebo (DRUG), Botulinum Toxin A (DRUG).
Who is sponsoring clinical trial NCT02677298?
This trial is sponsored by Croma-Pharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02677298's enrollment target sits among peer trials
784 433rd of 2000 higher than 1,568 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06118723 · 784 participants
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- NCT06498128 · 785 participants
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
- NCT06575192 · 783 participants · Phase 3
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
- NCT07276724 · 786 participants · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI